AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03422887
Drug: Flurbiprofen Axetil
RxNorm normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen axetil administration during surgery
Trial: NCT01903733
Drug: bosutinib
RxNorm normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The starting bosutinib dose is 500 mg once daily, however the dose can vary from 300 mg to 600 mg.
Trial: NCT06499181
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The primary objective is to examine differences in post-operative opioid consumption between the two groups.
Trial: NCT06499181
Drug: Bupivacain
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control group to receive 10cc of 0.5% bupivacaine with 1:50,000 epinephrine at the completion of the procedure per typical standard of care.
Trial: NCT06499181
Drug: Epinephrin
RxNorm normalized name: Epinephrin
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control group to receive 10cc of 0.5% bupivacaine with 1:50,000 epinephrine at the completion of the procedure per typical standard of care.
Trial: NCT02645370
Drug: Danzhen
RxNorm normalized name: Danziten
DrugBank: Nilotinib (DB04868)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02645370
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00043784
Drug: enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02877082
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT02877082
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV and PO
Trial: NCT03480750
Drug: trientine dihydrochloride
RxNorm normalized name: trientine dihydrochloride 300 MG Oral Capsule
DrugBank: Triethylenetetramine (DB06824)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: trientine dihydrochloride 300MG/CAPSUE PO daily (in different dose levels)
Trial: NCT00667979
Drug: Levitra (Vardenafil, BAY38-9456)
RxNorm normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg and 20mg to be taken 12, 18, 24 hours prior to sexual intercourse
Trial: NCT00394225
Drug: Oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00394225
Drug: Helium
RxNorm normalized name: Helium
DrugBank: Helium (DB09155)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03480750
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: carboplatin AUC 4 IV D1
Trial: NCT04022447
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: retrospective data collection
Trial: NCT02617810
Drug: JNJ-42847922
RxNorm normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ-42847922 20 milligram (mg) tablet orally once daily from Day 1 to Day 9.
Trial: NCT02617810
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive midazolam 4 milligram (mg) syrup orally once on Day 1 during treatment A and on Day 7 during treatment B.
Trial: NCT01988558
Drug: DL - Lactic Acid
RxNorm normalized name: DL-lactic acid
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treated group to receive DL - Lactic Acid Syrup (Raspberry flavored)
Trial: NCT03829683
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200mg/kg/24hours
Trial: NCT03829683
Drug: Dextrose 5% in water
RxNorm normalized name: LVP solution Dextrose 5% in Water intravenous solution
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mL intravenously every 6 hours
Trial: NCT01455844
Drug: CaPre (TM)
RxNorm normalized name: Caprelsa
DrugBank: Capreomycin (DB00314)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CaPre™ 1.0g + Placebo 1.0g daily for 12 weeks.
Trial: NCT01455844
Drug: CaPre (TM)
RxNorm normalized name: Caprelsa
DrugBank: Capreomycin (DB00314)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CaPre™ 2.0g daily for 12 weeks
Trial: NCT02617810
Drug: Warfarin
RxNorm normalized name: Warfarin
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive warfarin 25 milligram (mg) tablet orally once on Day 3 during treatment A and on Day 9 during treatment B.
Trial: NCT02397473
Drug: Galcanezumab
RxNorm normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered SC
Trial: NCT03419624
Drug: Dapagliflozin 10mg
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin 10 mg tablet once daily
Trial: NCT03419624
Drug: Exenatide 2 mg [Bydureon]
RxNorm normalized name: exenatide 2 MG [Bydureon]
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exenatide 2 mg injection once weekly
Trial: NCT03419624
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily Insulin injections
Trial: NCT03419624
Drug: Metformin, if taken before
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: If the Patient has taken Metformin prior to enrollment, he or she will continue to take it.
Trial: NCT01832194
Drug: Botox
RxNorm normalized name: Botox
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Trial: NCT02024971
Drug: Pioglitazone/metformin hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pioglitazone/metformin hydrochloride combination tablets
Trial: NCT00019760
Drug: floxuridine
RxNorm normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00019760
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01916226
Drug: Cetirizine
RxNorm normalized name: Cetirizine
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Over-encapsulated Cetirizine tablet with unit dose strength of 10 mg in High Density Poly Ethylene Bottles (20 count per bottle).
Trial: NCT01916226
Drug: Cetirizine Placebo
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Over-encapsulated Cetirizine matching tablet High Density Poly Ethylene Bottles (20 count per bottle).
Trial: NCT00261677
Drug: epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00723892
Drug: Rebetol (Ribavirin)
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Rebetol was administered orally based on the prescribed dose. The average dose for Rebetol was 950 ± 167.2 mg\^day
Trial: NCT00312091
Drug: Lamivudine, nevirapine, and stavudine fixed-dose tablet
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 7 mg d4T, 30 mg 3TC, 50 mg NVP tablet
Trial: NCT00312091
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosage dependent on weight. More information on this criterion can be found in the protocol.
Trial: NCT00312091
Drug: Nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage dependent on weight. More information on this criterion can be found in the protocol.
Trial: NCT00312091
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage dependent on weight. More information on this criterion can be found in the protocol.
Trial: NCT00020007
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00178828
Drug: sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be assigned by random selection to sertraline (50mg daily for one week, then 100mg daily) or bupropion (SR formulation, 150 mg daily for 1 week, then 150 mg BID). A second CSF collection will be completed after 4 weeks of the sertraline treatment (during week 5).
Trial: NCT00178828
Drug: bupropion
RxNorm normalized name: Bupropion
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be assigned by random selection to sertraline (50mg daily for one week, then 100mg daily) or bupropion (SR formulation, 150 mg daily for 1 week, then 150 mg BID). A second CSF collection will be completed after 4 weeks of the sertraline treatment (during week 5).
Trial: NCT03196479
Drug: ketamine and propofol mixture with 1:6 ratio
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: K16: K16 group was received ketamine:propofol with ratio of 1:6, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 30 ml of 1% propofol (10 mg/ml), and 19 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 6 mg of propofol
Trial: NCT03196479
Drug: ketamine and propofol mixture with 1:4 ratio
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: K14 group was received ketamine:propofol with ratio of 1:4, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 20 ml of 1% propofol (10 mg/ml), and 29 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 4 mg of propofol
Trial: NCT02420314
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: * Administered intravenously (IV)~* Prescribed at 200 mg/m2 (standard dose)~* Given once every 21 days (i.e., one cycle)~* Up to 4 cycles are administered depending on disease response
Trial: NCT02420314
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Administered intravenously (IV)~* Prescribed at AUC = 6 using the Cockcroft-Gault formula (standard dose)~* Given once every 21 days (i.e., one cycle)~* Up to 4 cycles are administered depending on disease response
Trial: NCT02062684
Drug: Blisibimod
RxNorm normalized name: Blisibimod
DrugBank: Blisibimod (DB12330)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02594579
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 100,000 u per day on day 1,3 then 50,000 u/day on day 5,7,9,12 and continue 50,000 u 3 times/ week for 4 weeks
Trial: NCT02915601
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03019653
Drug: ANX-042
RxNorm normalized name: hydroxyzine hydrochloride Oral Tablet [Anx]
DrugBank: Hydroxyzine (DB00557)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The first 20 subjects will receive a dose 0.003 µg/kg/min by infusion, the next 20 subjects will receive a dose of 0.006 µg/kg/min, then the next 20 subjects will receive 0.01 µg/kg/min.
Trial: NCT00135876
Drug: dalteparin
RxNorm normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04063462
Drug: Pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pyrotinib, single agent, 400mg p.o once daily until disease progressed
Trial: NCT04688294
Drug: Sacubitril-Valsartan
RxNorm normalized name: Sacubitril-Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 30 patients initially received Sacubitril/Valsartan at 24/26 mg twice daily orally then dose was doubled as tolerated every 2-4 weeks to reach the target maintenance dose 97 mg/103 mg twice daily
Trial: NCT01848457
Drug: Pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg IV over 15 min immediately prior to cisplatin as a loading dose on days 1 \& 2 followed by 1.3 mg/kg IV infused over 4 h concurrent with the 4 h cisplatin infusion on days 1 \& 2 of treatment Cycles 1 \& 2 (Treatment Arms 1, 3) OR Cycles 3 \& 4 (Treatment Arms 2, 4)
Trial: NCT00563316
Drug: Panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The first infusion of panitumumab will occur on Cycle 1 Day 4. On Cycle 2 Day 1, panitumumab will be administered on the same day as irinotecan and every 2 weeks thereafter.
Trial: NCT00563316
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The first infusion of irinotecan will occur on Cycle 1 Day 1. Irinotecan will be administered on the same day as panitumumab on Cycle 2 Day 1 and every 2 weeks thereafter.
Trial: NCT02770365
Drug: estrace cream (Perrigo)
RxNorm normalized name: estradiol Vaginal Cream [Estrace]
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02770365
Drug: estrace cream (Reference)
RxNorm normalized name: estradiol Vaginal Cream [Estrace]
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03620981
Drug: Brexpiprazole
RxNorm normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug: 1 tablet /day Once daily for 10 weeks
Trial: NCT03105765
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Application of Ketamine 0,2mg/kg ideal Body weight by Bolus before the Operation started, followed by application of 0,2 mg/kg ideal Body weight for 24 hours.
Trial: NCT00117442
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Chemotherapy
Trial: NCT00117442
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: chemotherapy
Trial: NCT00117442
Drug: pegfilgrastim
RxNorm normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Growth factor for mobilization
Trial: NCT01870583
Drug: Iodine povidone
RxNorm normalized name: POVIDONE IODINE
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Iodine skin preparation solution prior to cesarean delivery
Trial: NCT01870583
Drug: Chlorhexidine
RxNorm normalized name: Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorhexidine skin preparation solution prior to cesarean delivery
Trial: NCT01870583
Drug: Combination iodine and chlorhexidine
RxNorm normalized name: chlorhexidine, combinations
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination iodine povidone and chlorhexidine skin preparation solution prior to cesarean delivery
Trial: NCT03947385
Drug: Binimetinib
RxNorm normalized name: binimetinib
DrugBank: Binimetinib (DB11967)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Binimetinib dosed orally, twice daily for each 28-day cycle
Trial: NCT03947385
Drug: Crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Crizotinib dosed orally, twice daily for each 28-day cycle
Trial: NCT03633058
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral ketamine dosed twice daily for 5 days
Trial: NCT01627106
Drug: Vernakalant
RxNorm normalized name: vernakalant
DrugBank: Vernakalant (DB06217)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Initial intravenous (IV) dose of 3 mg/kg (up to a maximum of 339 mg) over 10 minutes, followed by a 15 minute observation period and, if conversion to sinus rhythm does not occur within 15 minutes of the initial infusion, a second 10 minute infusion of vernakalant at a dose of 2 mg/kg (up to a maximum of 226 mg) will be administered.
Trial: NCT01627106
Drug: Amiodarone
RxNorm normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered IV as per product label
Trial: NCT00532415
Drug: Triamcinolone Acetonide Injectable Suspension
RxNorm normalized name: triamcinolone acetonide Injectable Suspension
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.
Trial: NCT01878474
Drug: TA-8995
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TA-8905 5, 10, 25, 50 (fasted and fed), 100 and 150 mg
Trial: NCT01878474
Drug: TA-8995
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: TA-8995 25 mg
Trial: NCT01878474
Drug: TA-8995
RxNorm normalized name: Ta
DrugBank: Tantalum (DB12859)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: TA-8995 25, 50, 100 and 150 mg
Trial: NCT03228043
Drug: Apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib combine with CAPEOX adjuvant chemotherapy for resectable colorectal
Trial: NCT03440190
Drug: Methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are tested for their normal prescription methylphenidate medication
Trial: NCT03973489
Drug: Methamphetamine Hydrochloride Tablets
RxNorm normalized name: Methamphetamine Hydrochloride Tablets
DrugBank: Metamfetamine (DB01577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study participants will receive an oral dose of methamphetamine hydrochloride on one of two scan days and an identical looking placebo in tablet form on the other scan day. Drug type will be randomized between the two visits. Participants will receive the following doses of methamphetamine hydrochloride in accordance with their weight: if weight is between 50-60 kg, 15 mg dose of methamphetamine hydrochloride will be administered. Similarly, for 60-80 kg, 20 mg dose; 80-100 kg, 25 mg dose; and 100+ kg, 30 mg dose.
Trial: NCT02113813
Drug: naquotinib
RxNorm normalized name: Naquotinib
DrugBank: Naquotinib (DB12036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02113813
Drug: midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral
Trial: NCT03247673
Drug: CT-P16
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-P16 is a biosimilar product for Avastin
Trial: NCT03247673
Drug: EU-approved Avastin
RxNorm normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: EU-approved Avastin
Trial: NCT03247673
Drug: US-licensed Avastin
RxNorm normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: US-licensed Avastin
Trial: NCT04688294
Drug: Valsartan
RxNorm normalized name: Valsartan
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 30 patients received valsartan, starting at a dose of 40 mg/day orally. The dose was then doubled every 1-2 weeks on the basis of their blood pressure to reach a dose of 160 mg once daily according to guideline-directed medical therapy.
Trial: NCT03153202
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: once daily oral intake ibrutinib
Trial: NCT03153202
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg IV pembrolizumab on Day 1 of each cycle
Trial: NCT01887600
Drug: Roxadustat
RxNorm normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Roxadustat was administered initially according to the tiered weight-based dosing, where participants with weight from ≥ 45 to ≤ 70 kg received 70 mg and participants with \> 70 to ≤ 160 kg received 100 mg of roxadustat. Dose-titration based upon regular measurement of Hb levels was performed until participants achieved central Hb value of ≥ 11.0 g/dL and Hb increase from baseline (BL) of ≥ 1.0 g/dL at two consecutive study visits, separated by at least 5 days. Once target Hb level was reached participants entered maintenance period during which roxadustat dosage was adjusted every 4 weeks to maintain participants Hb level within the target range of 10.0 g/dL and 12.0 g/dL.
Trial: NCT00306098
Drug: islets
RxNorm normalized name: Autologous pancreatic islets
DrugBank: Autologous pancreatic islets (DB18521)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraportal infusion of islets
Trial: NCT00420056
Drug: PD-0332991
RxNorm normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 125 mg, oral, Days 1-21 of a 28-day cycle
Trial: NCT01105832
Drug: Teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teriparatide (Forsteo) 20 micrograms daily during four weeks
Trial: NCT00912873
Drug: 0.1% Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.1% will be administered via the perineural catheter as follows: Basal Rate (12mL/h); Basal Dose (12 mg/h); Bolus Volume (4 mL); Bolus Dose (4 mg); Lockout Duration (30 min); Maximum Dose (20 mg/h)